+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07732309

Evaluating the Safety and Effects of ATG-201 for Adults with Autoimmune Diseases in an Open-Label Phase I Study

Led by Antengene Biologics Limited · Updated on 2026-10-28

149

Participants Needed

22

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ATG-201, a recombinant human IgG1-like T cell engager, in adult participants with autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and Sjogrens disease. This phase I, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of ATG-201. The trial is sponsored by Antengene Biologics Limited and is conducted in two parts Dose Escalation and Dose Expansion. In Part I Dose Escalation, participants receive increasing doses of ATG-201 to identify the optimal biological dose OBD through nine preset dose levels. Part II Dose Expansion further explores and evaluates the OBDs identified. ATG-201 works by simultaneously binding to human CD3 and CD19, and the study is designed as a single-group, open-label trial without placebo or blinding. Participants will be closely monitored for safety and tolerability over 48 weeks, including assessments of pharmacokinetics and immunogenicity. Study visits and evaluations will track how the body processes ATG-201 and its effects on the immune system. Participants must adhere to visit schedules and contraceptive requirements if applicable, with safety monitoring continuing throughout the study until its completion in 2029.

CONDITIONS

Brief Title

A Study of ATG-201 in Adult Participants With Autoimmune Diseases

Research Team

I

Iris Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here